[{"orgOrder":0,"company":"Vista Pharm","sponsor":"Vista Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SucrAlphate","moa":"Pepsin A5","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Vista Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Vista Pharm \/ Vista Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Vista Pharm \/ Vista Pharm"}]

Find Clinical Drug Pipeline Developments & Deals by Vista Pharm

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : The approval of Sucralfate Oral Suspension, through initial development of twelve different bioassays that tracked product's postulated clinical interactions using in vitro biology, marks a paradigm shift in how complex generic drug products can be comme...

                          Product Name : Sucralfate-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 04, 2022

                          Lead Product(s) : SucrAlphate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Recipient : Clayton Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank